Cargando…

Gene expression and molecular pathway activation signatures of MYCN-amplified neuroblastomas

Neuroblastoma is a pediatric cancer arising from sympathetic nervous system. Remarkable heterogeneity in outcomes is one of its widely known features. One of the traits strongly associated with the unfavorable subtype is the amplification of oncogene MYCN. Here, we performed cross-platform biomarker...

Descripción completa

Detalles Bibliográficos
Autores principales:	Petrov, Ivan, Suntsova, Maria, Ilnitskaya, Elena, Roumiantsev, Sergey, Sorokin, Maxim, Garazha, Andrew, Spirin, Pavel, Lebedev, Timofey, Gaifullin, Nurshat, Larin, Sergey, Kovalchuk, Olga, Konovalov, Dmitry, Prassolov, Vladimir, Roumiantsev, Alexander, Buzdin, Anton
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2017
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5663553/ https://www.ncbi.nlm.nih.gov/pubmed/29137381 http://dx.doi.org/10.18632/oncotarget.19662

Ejemplares similares

Molecular pathway activation features of pediatric acute myeloid leukemia (AML) and acute lymphoblast leukemia (ALL) cells
por: Petrov, Ivan, et al.
Publicado: (2016)

Growth factor signaling predicts therapy resistance mechanisms and defines neuroblastoma subtypes
por: Lebedev, Timofey, et al.
Publicado: (2021)

Human Blood Serum Can Diminish EGFR-Targeted Inhibition of Squamous Carcinoma Cell Growth through Reactivation of MAPK and EGFR Pathways
por: Kamashev, Dmitri, et al.
Publicado: (2023)

Subtype of Neuroblastoma Cells with High KIT Expression Are Dependent on KIT and Its Knockdown Induces Compensatory Activation of Pro-Survival Signaling
por: Lebedev, Timofey, et al.
Publicado: (2022)

Atlas of RNA sequencing profiles for normal human tissues
por: Suntsova, Maria, et al.
Publicado: (2019)

New bioinformatic tool for quick identification of functionally relevant endogenous retroviral inserts in human genome
por: Garazha, Andrew, et al.
Publicado: (2015)

A systematic experimental evaluation of microRNA markers of human bladder cancer
por: Zabolotneva, Anastasia A., et al.
Publicado: (2013)

RNA Sequencing in Comparison to Immunohistochemistry for Measuring Cancer Biomarkers in Breast Cancer and Lung Cancer Specimens
por: Sorokin, Maxim, et al.
Publicado: (2020)

A method for predicting target drug efficiency in cancer based on the analysis of signaling pathway activation
por: Artemov, Artem, et al.
Publicado: (2015)

Retroelement—Linked Transcription Factor Binding Patterns Point to Quickly Developing Molecular Pathways in Human Evolution
por: Nikitin, Daniil, et al.
Publicado: (2019)

Correction: Nikitin, D., et al. Retroelement—Linked Transcription Factor Binding Patterns Point to Quickly Developing Molecular Pathways in Human Evolution. Cells 2019, 8, 130
por: Nikitin, Daniil, et al.
Publicado: (2019)

Selective Inhibition of HDAC Class I Sensitizes Leukemia and Neuroblastoma Cells to Anticancer Drugs
por: Vagapova, Elmira, et al.
Publicado: (2021)

Characteristic patterns of microRNA expression in human bladder cancer
por: Zabolotneva, Anastasia A., et al.
Publicado: (2013)

Machine Learning Applicability for Classification of PAD/VCD Chemotherapy Response Using 53 Multiple Myeloma RNA Sequencing Profiles
por: Borisov, Nicolas, et al.
Publicado: (2021)

Pathway Instability Is an Effective New Mutation-Based Type of Cancer Biomarkers
por: Zolotovskaia, Marianna A., et al.
Publicado: (2019)

Synergistic suppression of t(8;21)-positive leukemia cell growth by combining oridonin and MAPK1/ERK2 inhibitors
por: Spirin, Pavel, et al.
Publicado: (2017)

Gene Expression-Based Signature Can Predict Sorafenib Response in Kidney Cancer
por: Gudkov, Alexander, et al.
Publicado: (2022)

The MicroRNA Landscape of MYCN-Amplified Neuroblastoma
por: Misiak, Danny, et al.
Publicado: (2021)

MYCN is amplified during S phase, and c-myb is involved in controlling MYCN expression and amplification in MYCN-amplified neuroblastoma cell lines
por: Aygun, Nevim, et al.
Publicado: (2019)

MYCN upregulates the transsulfuration pathway to suppress the ferroptotic vulnerability in MYCN-amplified neuroblastoma
por: Floros, Konstantinos V., et al.
Publicado: (2022)

Novel robust biomarkers for human bladder cancer based on activation of intracellular signaling pathways
por: Lezhnina, Ksenia, et al.
Publicado: (2014)

Algorithmically Reconstructed Molecular Pathways as the New Generation of Prognostic Molecular Biomarkers in Human Solid Cancers
por: Zolotovskaia, Marianna, et al.
Publicado: (2023)

MYCN acts as a direct co-regulator of p53 in MYCN amplified neuroblastoma
por: Agarwal, Saurabh, et al.
Publicado: (2018)

A MYCN-independent mechanism mediating secretome reprogramming and metastasis in MYCN-amplified neuroblastoma
por: Zhang, Hai-Feng, et al.
Publicado: (2023)

Mutation Enrichment and Transcriptomic Activation Signatures of 419 Molecular Pathways in Cancer
por: Zolotovskaia, Marianna A., et al.
Publicado: (2020)

PB1760: PREDICTION OF DRUG SENSITIVITY AND GENETIC VULNERABILITY FOR ACUTE LEUKEMIA SUBTYPES USING GRAPH OF SIGNALING PATHWAY CORRELATIONS.
por: Lebedev, Timofey, et al.
Publicado: (2023)

Genomic profile of MYCN non-amplified neuroblastoma and potential for immunotherapeutic strategies in neuroblastoma
por: Lee, Eunjin, et al.
Publicado: (2020)

Correction: MYCN acts as a direct co-regulator of p53 in MYCN amplified neuroblastoma
por: Agarwal, Saurabh, et al.
Publicado: (2018)

Elimination of MYCN-Amplified Neuroblastoma Cells by Telomerase-Targeted Oncolytic Virus via MYCN Suppression
por: Tanimoto, Terutaka, et al.
Publicado: (2020)

Combinatorial high-throughput experimental and bioinformatic approach identifies molecular pathways linked with the sensitivity to anticancer target drugs
por: Venkova, Larisa, et al.
Publicado: (2015)

Targeting condensin, a vital spot of MYCN-amplified neuroblastoma
por: Tanno, Yuji, et al.
Publicado: (2014)

Multi-omic profiling of MYCN-amplified neuroblastoma cell-lines
por: Dassi, Erik, et al.
Publicado: (2015)

Inhibitors of ribosome biogenesis repress the growth of MYCN-amplified neuroblastoma
por: Hald, Øyvind H., et al.
Publicado: (2018)

CAMKV Is a Candidate Immunotherapeutic Target in MYCN Amplified Neuroblastoma
por: Sussman, Robyn T., et al.
Publicado: (2020)

FOXR2 Stabilizes MYCN Protein and Identifies Non–MYCN-Amplified Neuroblastoma Patients With Unfavorable Outcome
por: Schmitt-Hoffner, Felix, et al.
Publicado: (2021)

SMAD9-MYCN positive feedback loop represents a unique dependency for MYCN-amplified neuroblastoma
por: Tan, Kezhe, et al.
Publicado: (2022)

Two Receptors, Two Isoforms, Two Cancers: Comprehensive Analysis of KIT and TrkA Expression in Neuroblastoma and Acute Myeloid Leukemia
por: Lebedev, Timofey D., et al.
Publicado: (2019)

DNA repair pathway activation features in follicular and papillary thyroid tumors, interrogated using 95 experimental RNA sequencing profiles
por: Vladimirova, Uliana, et al.
Publicado: (2021)

The genetic tumor background is an important determinant for heterogeneous MYCN‐amplified neuroblastoma
por: Bogen, Dominik, et al.
Publicado: (2016)

Serine–glycine-one-carbon metabolism: vulnerabilities in MYCN-amplified neuroblastoma
por: Zhao, Erhu, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_k4p0sbl0svruets0cbqa3uqoio